How Investors can Capitalize on Healthcare Growth

Healthcare isn’t sexy. But in 2025, it’s quietly becoming the smartest play in Indian VC. India's VC funding grew 40% in Jan–Feb 2025, even as the global markets cooled. Within this surge, healthcare has emerged not just as a resilient sector but as one of the most strategically favoured verticals. This shift isn’t incidental. It’s being driven by a very real behavioural pivot. 1) Indian consumers, particularly in Tier 1 and urban Tier 2, are moving decisively from reactive to proactive healthcare. 2) There is growing willingness to pay for diagnostics, preventive care, and ongoing wellness services. Healthcare is no longer something to turn to in crisis — it's becoming a monthly subscription decision, a daily app notification, a data-driven lifestyle choice. On the delivery side, investors are moving away from capital-heavy multispecialty hospitals toward scalable, asset-light models. Single-specialty chains in categories like fertility, ophthalmology, orthopaedics, and dermatology are becoming favoured targets. They offer sharper operational visibility, lower complexity, and faster paths to profitability, all of which align perfectly with current VC risk appetite. Diagnostics, too, is undergoing a transformation with significant interest in digital-first, at-home, and B2B diagnostics platforms. When combined with health SaaS, workflow automation, and AI-enabled diagnostics, the thesis becomes not just consumer-facing health, but infra-first healthcare. Parallelly, India’s medtech and pharmaceutical manufacturing sectors are benefiting from global realignment. As global players diversify away from China, India’s high-quality, low-cost base is becoming strategically important. Private equity interest is rising in CDMO platforms, API manufacturers, and device exporters. These businesses offer forex-linked revenue, regulatory clarity, and strong M&A appetite from strategic buyers. Across the board, the VC lens in 2025 is more thesis-led and less trend-driven. Investors are optimising for clear profitability paths, clean cap tables, recurring revenue models, and compliance hygiene. Healthtech models with real operating leverage are being favoured over B2C plays chasing vanity growth. In short, this is not a post-pandemic sector play. It’s a structural investment shift. Healthcare in India is maturing, in demand, delivery, and investor mindset. #100DaysLinkedIn #healthcare #VC

Why Medical Outpatient Buildings Are Gaining Investor Attention - Healthcare delivery continues to shift away from hospitals and into lower-cost outpatient settings — and investors are taking note. Medical outpatient buildings (MOBs) are positioned to benefit from one of the strongest demographic and economic tailwinds in the U.S. Here’s why: 📈 Durable Demand Americans over age 65 account for just 17% of the population but 37% of all healthcare spending — and that population is projected to rise from 56M to nearly 95M by 2060. 🏥 Recession-Resistant Cash Flow Healthcare spending remained resilient through the last three economic downturns and currently represents 18.5% of U.S. GDP — with expected annual growth of ~5%. Cash flows tied to essential healthcare services have historically shown low correlation to broader economic cycles. 📌 Strong Occupancy & Retention Medical outpatient assets maintain exceptionally high occupancy — 93% in 4Q24, materially higher than traditional office — and renew at far stronger rates. 💸 Attractive Entry Pricing & Positive Leverage Today’s market features average cap rates ranging from 6.4% to 7.0% for MOB acquisitions in the 30k - 50k square foot range. With fixed-rate medical debt currently costing less than cap rates, investors can capture positive leverage from day one. 🌎 Aligns With U.S. Healthcare Transformation Same-day surgery, specialty care, diagnostic services, and lower-cost treatment settings are all growing rapidly. That accelerates tenant demand for modern outpatient facilities — particularly in high-growth regions such as Texas and the Southeast. Bottom Line: Medical outpatient buildings combine durable tenant demand, sticky occupancy, and stable cash flow — all backed by a demographic wave that will continue building for decades. For investors seeking consistent income with insulation from economic volatility, MOBs may be one of the most compelling opportunities in today’s private real estate market. https://lnkd.in/g8gvCugr to learn more.

Turns out the best investment opportunities in healthcare are hiding in nausea, gallstones, and constipation. In recent conversations with several large healthcare private equity funds, the consensus is clear: GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are not just transforming obesity care. They are quietly creating a secondary gold rush in treating the side effects of weight loss. And it is not small. More than 6 million Americans are already on GLP-1s. Global GLP-1 sales are expected to exceed 130 billion dollars annually by 2030. Up to 40 percent of patients experience significant gastrointestinal side effects. Around 5 to 7 percent end up with gallbladder complications. Sarcopenia is now a real concern. Mental health utilization among GLP-1 users is rising by nearly 20 percent. Fertility clinics are seeing double-digit growth from GLP-1-related cases. So while everyone is applauding the miracle of weight loss, the savviest investors are looking at the flip side. They are rolling up GI clinics, expanding ASC platforms with cholecystectomy capacity, funding digital fitness and nutrition programs to fight muscle loss, backing behavioral health services for body image and binge relapse, and building analytics tools to help payers track it all. It is not just a new drug. It is a new healthcare economy. I have unpacked this trend in detail in my latest white paper: a playbook for investing around the GLP-1 explosion by targeting the ripple effects no one is talking about. Because in healthcare, what goes down (appetite) must come up (utilization of something else). #PrivateEquity #Healthcare #GLP1 #OzempicEconomy #HealthTech #DigitalHealth #VentureCapital #ObesityCare #PEInvesting

Value creation in a private equity environment revolves around systematically enhancing a portfolio company’s performance to achieve strong returns at exit. In my recent role as Go-to-Market Advisor for a cutting-edge AI-led health tech startup in the UK at Series B, I developed a comprehensive commercial strategy that rapidly boosted recurring revenue by 30% within 12 months. A key breakthrough emerged when we discovered extended integration timelines were deterring smaller clinics and hospital networks from adopting our solution. By designing a flexible onboarding framework, we reduced implementation time by 40% and reinvested these savings into predictive analytics features—enabling clinicians to forecast patient needs and administrators to allocate resources more effectively. Here’s a concise six-step roadmap for delivering tangible results: 1. Due Diligence: Pinpoint growth levers and operational bottlenecks pre-acquisition. 2. 100-Day Plan: Establish quick wins—revamp pricing structures, refine workflows, and optimise early partnerships. 3. Organisational Excellence: Assess leadership, align incentives with performance outcomes, and foster a culture of continuous improvement. 4. Accelerated Growth: Perfect go-to-market strategies, drive product innovation, and explore targeted acquisitions or strategic alliances. 5. Ongoing Optimisation: Monitor KPIs rigorously, remain agile, and leverage real-time data insights to pivot swiftly. 6. Exit Preparation: Ensure robust financial reporting, demonstrate sustained operational gains, and plan a smooth transition for new owners. Throughout each phase, transparency and collaboration are vital. Regular, data-driven updates to board members, management teams, and front-line staff help secure buy-in and maintain accountability. Ultimately, true value creation goes beyond financial engineering. It’s about generating sustainable growth, driving innovation, strengthening the organisation’s culture, and positioning the business for long-term success. By following a deliberate plan and staying laser-focused on top-line expansion and bottom-line efficiency, we set the stage for a transformative exit that benefits stakeholders and the broader healthcare ecosystem alike.

The longevity and health care opportunity has not seen the same stock market traction as AI and power and resources over the past year. This presents an opportunity. Friday’s sell‑off was a reminder that health care is a key ingredient to a diversified portfolio. While the S&P fell 2.6%, the health care sector rose 0.6%, consistent with its low correlation to the S&P over the last twelve months. But it is not only a defensive play. The US pharma sector, which has outperformed the Mag 7 so far this year, is rapidly moving to innovation driven growth, with upside that is underappreciated, in our view. GLP-1 drugs may be creating one of the largest new drug markets in pharmaceutical history, shifting the paradigm from treating the consequences to treating the root cause of diseases. At the same time, a powerful convergence of AI and advanced genomics is changing how drugs are discovered, lowering failure rates and improving returns on invested capital. Structural changes in the global population provide a further tailwind, with an aging population creating a growing demand for advanced therapies.

Capital is still moving in digital health — but it’s doing so with far more intent. 2025 didn’t mark a retreat in global venture funding. It marked a reallocation. Money flowed toward therapeutic areas and clusters that solve immediate, measurable healthcare problems — and away from those still searching for proof of impact. Oncology remained the most funded therapeutic area at $3.6B. But the headline number hides a harder truth: funding declined 12% year over year. That’s not a loss of belief in oncology. It’s investor discipline catching up to complexity, timelines, and capital intensity. Oncology is still essential — but fewer bets are being placed, and only on platforms with clear differentiation. The more interesting signal sits elsewhere. Preventive Health surged 104% in 2025. That’s not a rounding error. That’s conviction. Companies like Neko Health and ŌURA didn’t just raise capital — they validated a thesis: prevention is no longer a wellness side quest. It’s becoming core healthcare infrastructure. Continuous monitoring, risk detection, and proactive intervention now look investable at scale. The same story is playing out across digital health clusters. Health Management Solutions grew 50% year over year, overtaking Research Solutions to become the top-funded cluster. Meanwhile, Research Solutions aka TechBio fell 19%, and Medical Diagnostics dropped 33%. This isn’t anti-science. It’s pro-execution. Investors are prioritising platforms that help systems run better today — care coordination, chronic disease management, workflow optimisation — over tools that promise future insight but lack near-term revenue gravity. Telemedicine (+55%) and Wellness (+74%) reinforce the pattern: adoption, not novelty, is driving checks. My takeaway: 2025 funding data isn’t about optimism or pessimism. It’s about selectivity. Capital is flowing to business models that shorten feedback loops, prove outcomes, and integrate into real healthcare workflows — not just impressive decks. If you’re building in digital health, the bar is clear: Show where you sit in the care journey. Show who pays. Show why now. If you’re navigating this shift, I’m happy to compare notes. Further Reading Report: https://lnkd.in/efRBp676 Op-ed: https://lnkd.in/eBzrUbDY Research: https://lnkd.in/efqcmmzH #DigitalHealth #HealthTech #VentureCapital #techbio #prevention #2025

After more than two decades of investing in healthcare, I've learned three things: be patient, resist trend-chasing, and wait until timing makes sense. With experience on dozens of boards, witnessing thousands of pitches, navigating frothy portfolio activity, and surviving the dud markets while waiting on good ones to return, I know that time and timing is key for success in healthcare investing. The challenge is, how do I convince LPs that the wait will be worth it? Peek at Relentless Venture Fund diversity of companies that span regenerative medicine to software-as-a-medical-device (SaMD), includes a repeat entrepreneur who practiced medicine, to technical founders who figured out IP rights in a way that only newbies to the industry would contemplate. The beauty of diversified portfolio construction, regulatory and risk balance. Deep bets take time. That's the opportunity in healthcare investing. BC has structural advantages that make deep bets work. World-class science from The University of British Columbia, Simon Fraser University, University of Victoria, BCCA and our research hospitals. Clinical trial facilities such as the new Phase 1 Clinical Trial Unit at Providence Health Care. Provincial commitment to the innovation ecosystem such as the government's participation in Aspect Biosystems' $200M, multi-year project to ensure a world class team thrives in a world class facility in our province. What would further amplify our potential? Procurement strategies that let BC companies prove themselves locally before going global. As a member of DIGITAL's investment committee, I evaluate and advance private/public partnerships that derisk technology and accelerate commercial adoption in BC and across Canada. These collaborations are shortening the path from lab to market. Timelines for liquidity in healthcare may be longer than other venture sectors, but the wins are foreshadowed years ahead. Canary Medical Inc. locked in a commercial partnership with Zimmer Biomet before regulatory approval. Aspect secured a $2.6B partnership with Novo Nordisk on pre-clinical data. Two BC founded, Relentless portfolio companies. It will be approximately one decade from our original investment in Aspect to their first human clinical trial. I am not fussed by the timeline. Each strategic partnership and validation of data by customers sets the stage for a high value exit. The beauty of investing in healthcare innovation is regulatory timelines are getting shorter and costs are dropping; innovation is expediting discovery, diagnosis, treatment and care options never imagined when I started my VC career. I know deep science takes time, and patient capital wins. And when they do, BC has an opportunity to capture value that historically flowed south. With the right policy support and patient capital aligned, we can continue to build category defining healthcare companies that scale from our province, not just launch here and relocate. Life Sciences BC

The Quant Investor's Guide to Preventative Healthcare! Quant investment in healthcare isn't just about allocating capital; it's about strategically deploying resources based on rigorous data analysis to maximize clinical impact, particularly in prevention. We're talking about leveraging sophisticated quantitative methodologies to identify high-yield opportunities in proactive health strategies. Think about it: instead of broad-stroke wellness initiatives, quant analysis allows us to pinpoint specific preventative interventions – whether it's targeted nutritional programs based on genetic predispositions or digital health tools for early risk detection in specific demographics – that demonstrate the highest potential for positive outcomes. Investment decisions are driven by predictive models that forecast the clinical benefits and long-term value of these preventative measures. This data-centric approach demands continuous monitoring and evaluation. Key performance indicators, derived from real-world data, inform ongoing investment adjustments, ensuring resources are consistently directed towards the most effective preventative strategies. Ultimately, quant investment in prevention is about optimizing healthcare spend by proactively mitigating disease risk and fostering a healthier population. #QuantInvesting #HealthcareInnovation #PreventativeCare #DataDrivenDecisions #HealthEconomics #InvestmentStrategy #FutureofHealthcare

Most healthcare startups that scale aren’t pure tech — they’re tech-enabled services that follow the "80/20 Health Tech Rule": 20% tech → 80% adoption, workflow fit, and operational execution. Some recent companies doing it right: Marigold Health uses AI for peer-supported mental health, but the real product is a Medicaid-aligned care model staffed by peer counselors and behavioral health coordinators. The tech supports scale, but trust and engagement drive outcomes. Memora Health - a backend for care continuity - automating post-discharge communication, but tightly integrated into EHRs and hospital ops. Their success is not on tech novelty but on the lift they take off care teams. KeyCare is building a virtualist workforce on top of Epic - the secret is not the telehealth software, it’s that they’re the only virtual care group embedded directly into health systems’ EHRs. Cortex Health offers hospital-at-home. Yes, there’s tech, but the real differentiator is the service layer that aligns with post-acute reimbursement models. They know tech alone can’t fix home health fragmentation. Accompany Health targets the highest-need dual-eligible patients with in-home care. Again, there’s a tech platform — but they lead with field ops, trust-building, and Medicaid-native contracting strategy. In every case, tech is the enabler, not the product. Yet many startups still build 80% tech and expect behavior change. In healthcare, that rarely works. For investors, start by asking: Is this an ops company disguised as software? That’s where the real returns live. For founders, if adoption isn’t baked into your product, you’re not building a company - you’re building a demo. #PhyCap Fund#techenabled